(Total Views: 608)
Posted On: 03/31/2021 10:36:12 PM
Post# of 30066
85,586,795 Todos shares owned by AMARANTUS ,
In addition a 10% royalty on LymPro intellectual property.
(LymPro Test™has been valued at $136 million by an independent third-party valuation firm...)
On July 28, 2020, Todos Medical Ltd. (the “Company”) entered into Amendment No. 1 to the Binding Joint Venture Agreement with Amarantus Bioscience Holdings, Inc.
(“Amarantus”) pursuant to which the parties agreed that the Company would issue 49.9% of its ordinary shares as of December 31, 2019 to Amarantus in exchange for the
80.1% equity interest it does not own of Breakthrough Diagnostics, Inc. In addition, Amarantus will receive a 10% royalty on LymPro intellectual property.
In addition a 10% royalty on LymPro intellectual property.
(LymPro Test™has been valued at $136 million by an independent third-party valuation firm...)
On July 28, 2020, Todos Medical Ltd. (the “Company”) entered into Amendment No. 1 to the Binding Joint Venture Agreement with Amarantus Bioscience Holdings, Inc.
(“Amarantus”) pursuant to which the parties agreed that the Company would issue 49.9% of its ordinary shares as of December 31, 2019 to Amarantus in exchange for the
80.1% equity interest it does not own of Breakthrough Diagnostics, Inc. In addition, Amarantus will receive a 10% royalty on LymPro intellectual property.
(1)
(0)
